LYRA Insider Trading
Insider Ownership Percentage: 3.25%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $546,822.64
Lyra Therapeutics Share Price & Price History
Current Price: $4.50
Price Change: ▲ Price Increase of +0.31 (7.40%)
As of 12/4/2025 05:00 PM ET
Lyra Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/13/2025 | Perceptive Advisors Llc | Major Shareholder | Sell | 31,810 | $3.90 | $124,059.00 | 14,026 | |
| 11/12/2025 | Perceptive Advisors Llc | Major Shareholder | Sell | 8,745 | $4.06 | $35,504.70 | 17,239 | |
| 11/11/2025 | Perceptive Advisors Llc | Major Shareholder | Sell | 5,320 | $4.31 | $22,929.20 | 18,122 | |
| 11/10/2025 | Perceptive Advisors Llc | Major Shareholder | Sell | 18,502 | $4.54 | $83,999.08 | 18,659 | |
| 11/7/2025 | Perceptive Advisors Llc | Major Shareholder | Sell | 19,739 | $4.75 | $93,760.25 | 20,528 | |
| 11/6/2025 | Perceptive Advisors Llc | Major Shareholder | Sell | 32,149 | $5.18 | $166,531.82 | 22,521 | |
| 7/10/2025 | Jason Cavalier | CFO | Sell | 684 | $8.91 | $6,094.44 | 519,316 | |
| 7/10/2025 | Maria Palasis | CEO | Sell | 1,565 | $8.91 | $13,944.15 | 1,098,435 | |
| 11/10/2023 | Harlan Waksal | Insider | Buy | 500 | $148.00 | $74,000.00 | 5,239 | |
| 5/31/2023 | Nbvm Gp, Llc | Major Shareholder | Buy | 36,108 | $121.50 | $4,387,122.00 | 50,434 | |
| 5/31/2023 | Perceptive Advisors Llc | Director | Buy | 72,216 | $124.50 | $8,990,892.00 | 229,382 | |
Lyra Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Citadel Advisors LLC | 19,484 | $0.13M | 0.0% | N/A | 1.101% |  |
| 8/15/2025 | Perceptive Advisors LLC | 255,150 | $2.29M | 0.2% | -98.0% | 15.558% |  |
| 8/15/2025 | Bank of America Corp DE | 28,542 | $0.26M | 0.0% | +33.7% | 1.740% |  |
| 8/8/2025 | Geode Capital Management LLC | 10,986 | $98K | 0.0% | -98.9% | 0.687% |  |
| 6/27/2025 | Goldman Sachs Group Inc. | 370,194 | $47K | 0.0% | -33.4% | 27.834% |  |
| 5/16/2025 | Goldman Sachs Group Inc. | 370,194 | $47K | 0.0% | -33.4% | 0.559% |  |
| 2/17/2025 | Two Sigma Investments LP | 209,997 | $43K | 0.0% | -25.7% | 0.321% |  |
| 2/17/2025 | Two Sigma Advisers LP | 385,500 | $80K | 0.0% | -16.3% | 0.589% |  |
| 2/17/2025 | BNP Paribas Financial Markets | 244,920 | $51K | 0.0% | N/A | 0.374% |  |
| 2/14/2025 | Samsara BioCapital LLC | 1,965,689 | $0.41M | 0.1% | -29.3% | 3.003% |  |
| 2/14/2025 | Northern Trust Corp | 286,310 | $59K | 0.0% | +56.2% | 0.437% |  |
| 2/13/2025 | ADAR1 Capital Management LLC | 533,200 | $0.11M | 0.0% | N/A | 0.815% |  |
| 2/12/2025 | Geode Capital Management LLC | 885,966 | $0.18M | 0.0% | +15.3% | 1.353% |  |
| 2/12/2025 | JPMorgan Chase & Co. | 156,442 | $32K | 0.0% | +161.8% | 0.239% |  |
| 11/15/2024 | State Street Corp | 488,720 | $0.13M | 0.0% | +88.1% | 0.747% |  |
| 8/6/2024 | Acadian Asset Management LLC | 985,631 | $0.27M | 0.0% | N/A | 1.617% |  |
| 7/12/2024 | Rosalind Advisors Inc. | 1,034,773 | $0.29M | 0.2% | -9.6% | 1.697% |  |
| 5/17/2024 | Ikarian Capital LLC | 1,056,829 | $6.57M | 0.7% | -15.7% | 1.733% |  |
| 5/10/2024 | Vanguard Group Inc. | 1,481,481 | $9.22M | 0.0% | +38.3% | 2.430% |  |
| 4/25/2024 | Rosalind Advisors Inc. | 1,144,524 | $7.12M | 6.7% | -39.4% | 1.916% |  |
| 2/15/2024 | Parkman Healthcare Partners LLC | 754,885 | $3.96M | 0.6% | +20.8% | 1.436% |  |
| 2/14/2024 | Vestal Point Capital LP | 3,000,000 | $15.72M | 1.7% | N/A | 5.708% |  |
| 2/13/2024 | Armistice Capital LLC | 1,088,000 | $5.70M | 0.1% | -29.8% | 2.070% |  |
| 2/7/2024 | Jump Financial LLC | 16,737 | $88K | 0.0% | N/A | 0.032% |  |
| 1/25/2024 | Heritage Wealth Management Inc. Texas | 10,000 | $52K | 0.0% | N/A | 0.019% |  |
| 12/6/2023 | Citigroup Inc. | 67,677 | $0.27M | 0.0% | N/A | 0.129% |  |
| 11/15/2023 | Armistice Capital LLC | 1,550,000 | $6.06M | 0.1% | -61.4% | 2.949% |  |
| 11/14/2023 | Prescott Group Capital Management L.L.C. | 30,000 | $0.12M | 0.0% | N/A | 0.057% |  |
| 10/24/2023 | Bank of New York Mellon Corp | 18,621 | $73K | 0.0% | N/A | 0.038% |  |
| 8/24/2023 | Perceptive Advisors LLC | 12,757,562 | $52.43M | 1.5% | +39.5% | 25.747% |  |
| 8/14/2023 | Samsara BioCapital LLC | 2,780,261 | $11.43M | 2.0% | +56.4% | 8.733% |  |
| 8/14/2023 | Pura Vida Investments LLC | 1,413,242 | $5.72M | 0.8% | -29.2% | 4.439% |  |
| 8/10/2023 | Letko Brosseau & Associates Inc. | 31,900 | $0.13M | 0.0% | N/A | 0.100% |  |
| 2/15/2023 | Nantahala Capital Management LLC | 2,220,830 | $6.97M | 0.5% | -1.1% | 6.977% |  |
| 2/14/2023 | Pura Vida Investments LLC | 2,157,298 | $6.77M | 0.3% | -14.1% | 6.778% |  |
| 11/15/2022 | Pura Vida Investments LLC | 2,510,302 | $12.58M | 0.7% | -2.6% | 7.888% |  |
| 11/14/2022 | Boothbay Fund Management LLC | 34,721 | $0.17M | 0.0% | -9.5% | 0.109% |  |
| 11/10/2022 | Nantahala Capital Management LLC | 2,245,830 | $11.25M | 0.7% | -5.2% | 17.262% |  |
| 8/16/2022 | Pura Vida Investments LLC | 2,576,196 | $14.56M | 0.8% | +394.9% | 19.802% |  |
| 8/16/2022 | CVI Holdings LLC | 60,822 | $0.34M | 0.0% | N/A | 0.468% |  |
| 8/15/2022 | Nantahala Capital Management LLC | 2,369,668 | $13.39M | 0.7% | N/A | 18.214% |  |
| 8/12/2022 | Ensign Peak Advisors Inc | 56,229 | $0.32M | 0.0% | +43.6% | 0.432% |  |
| 8/12/2022 | Ikarian Capital LLC | 347,338 | $1.96M | 0.4% | -17.8% | 2.670% |  |
| 5/16/2022 | Clearline Capital LP | 119,924 | $0.48M | 0.1% | +84.9% | 0.922% |  |
| 2/14/2022 | Clearline Capital LP | 64,862 | $0.28M | 0.0% | N/A | 0.499% |  |
| 2/14/2022 | Soleus Capital Management L.P. | 10,000 | $44K | 0.0% | -95.4% | 0.077% |  |
| 2/11/2022 | Pentwater Capital Management LP | 71,313 | $0.31M | 0.0% | +122.8% | 0.548% |  |
| 11/16/2021 | Two Sigma Advisers LP | 58,000 | $0.53M | 0.0% | +31.8% | 0.446% |  |
| 11/15/2021 | Pura Vida Investments LLC | 533,417 | $4.87M | 0.1% | -1.7% | 4.103% |  |
| 11/15/2021 | Marshall Wace LLP | 12,457 | $0.11M | 0.0% | -35.5% | 0.096% |  |
| 11/9/2021 | BlackRock Inc. | 17,818 | $0.16M | 0.0% | -11.4% | 0.137% |  |
| 11/4/2021 | Close Asset Management Ltd | 7,000 | $64K | 0.0% | N/A | 0.054% |  |
| 8/17/2021 | Millennium Management LLC | 155,135 | $1.25M | 0.0% | N/A | 1.193% |  |
Data available starting January 2016
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Read More on Lyra Therapeutics
Volume
46,688 shs
Average Volume
96,320 shs
Market Capitalization
$7.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Lyra Therapeutics?
Who are the major institutional investors of Lyra Therapeutics?
Which major investors are buying Lyra Therapeutics stock?
During the previous quarter, LYRA stock was acquired by institutional investors including:
- Citadel Advisors LLC